Lethal VR Free Download
Get ready for some fast-paced action as VR XRacer is fully readied to ramp up your adrenaline! You have to lead your team to safeguard the earth from the UFO spaceship attacks. Make the best use of destructive missiles and lethal weapons to destroy the enemies.
Lethal VR Free Download
Ready to indulge in a superb game of heroics? Romans From Mars 360 can be as addictive as it can ever get. As a Roman soldier, you have to fight against the invading Martin Army. Make the best use of the hands-free movement to attack your enemies with arrows. You are powerful enough to use not just fire, ice, lightning but also earth to win the war against your enemies.
People love free steam games, no doubt. But what many people hate is downloading so many parts and trying to install them on their own. This is why we are the only site that pre-installs every game for you. We have many categories like shooters, action, racing, simulators and even VR games! We strive to satisfy our users and ask for nothing in return. We revolutionized the downloading scene and will continue being your #1 site for free games.
- Feel free to redistribute this mod in unedited form on any page other than nexusmods.com, under the conditions that 1) you give me credit for the work I have done, 2) clearly state that any users of whatever page you upload to should not start bothering me for support, and 3) you are not asking users to pay for the mod.- Feel free to redistribute this mod in edited form on nexusmods.com (or any other page), under the same conditions as above.- Looking at how I implemented features and using some parts in other mods is fine, assuming that 1) you give me credit for the work I have done, and 2) you are not asking users to pay for the mod.- Feel free to feature this mod in any kinds of videos. I would appreciate if you can include a link to the mod page somewhere, and if you could let me know about featuring the mod in any videos such that I can also link to it from the mod page.
We are currently witnessing a democratisation of new and emerging technologies. While technology can be a driver of development and prosperity, it can also be instrumentalised by extremists who can exploit them in unanticipated and lethal ways.
While policy makers need to counter the use of existing technologies by violent non-state actors, they also need to keep an eye on emerging technologies. In the past military technology tended to develop in a closed system, whereas today we have entered a stage of unprecedented open innovation. Individuals and private groups are free to not only buy, use, and distribute them, but also to invent and repurpose them.
Perinatal-lethal Gaucher disease is very rare and is considered a variant of type 2 Gaucher disease that occurs in the neonatal period. The most distinct features of perinatal-lethal Gaucher disease are non-immune hydrops fetalis, in utero fetal demise and neonatal distress. In some cases without hydrops, neurological signs occur in the first week of life and lead to death within 3 months. Less common signs of the disease are hepatosplenomegaly, ichthyosis, arthrogryposis and facial dysmorphy. We describe a preterm neonate with Gaucher disease homozygous for R463H mutation in GBA gene who showed severe neurologic signs in addition to refractory thrombocytopenia, hepatosplenomagaly, direct hyperbilirubinemia, facial dysmorphy and ichthyosiform skin abnormalities in addition to having thrombosis in portal and splenic veins possibly due to homozygosity for C677T mutation in MTHFR gene. To the best of our knowledge, this is the first case homozygous for the GBA R463H mutation resulting in Gaucher disease with a concomitant homozygous MTHFR C677T mutation.
Isocitrate dehydrogenase 1 and 2 (IDH) are mutated in multiple cancers and drive production of (R)-2-hydroxyglutarate (2HG). We identified a lipid synthesis enzyme [acetyl CoA carboxylase 1 (ACC1)] as a synthetic lethal target in mutant IDH1 (mIDH1), but not mIDH2, cancers. Here, we analyzed the metabolome of primary acute myeloid leukemia (AML) blasts and identified an mIDH1-specific reduction in fatty acids. mIDH1 also induced a switch to b-oxidation indicating reprogramming of metabolism toward a reliance on fatty acids. Compared with mIDH2, mIDH1 AML displayed depletion of NADPH with defective reductive carboxylation that was not rescued by the mIDH1-specific inhibitor ivosidenib. In xenograft models, a lipid-free diet markedly slowed the growth of mIDH1 AML, but not healthy CD34+ hematopoietic stem/progenitor cells or mIDH2 AML. Genetic and pharmacologic targeting of ACC1 resulted in the growth inhibition of mIDH1 cancers not reversible by ivosidenib. Critically, the pharmacologic targeting of ACC1 improved the sensitivity of mIDH1 AML to venetoclax.
MiSL predicts ACC1 as a metabolic dependency for mutant IDH1, but not mutant IDH2. A, Schematic showing MiSL algorithm and prediction of ACC1 (ACACA) as a potential synthetic lethal partner of mutant IDH1 across pan-cancer. CNA, copy-number alteration. B,ACC1 mRNA expression comparing mutated IDH1 and IDH2 AML vs. wild-type in The Cancer Genome Atlas based on RNA sequencing data. Differences in expression were compared with Student t test with P values as shown. C, Validation of ACC1-specific hairpins on protein expression by Western blot (left) with quantification (right). Experiment was performed 3 independent times. *, P D, ACC1-specific hairpins with mRNA quantified by TaqMan qPCR compared with nontargeting shRNA. Experiment was performed in triplicate 2 independent times; ***, P E, Knockdown of ACC1 using shRNA#1 (left) or shRNA#2 (right) in THP-1 cells expressing IDH1 R132H (mIDH1) or IDH2 R140Q (mIDH2) under dox-induced promoter in lipid-depleted media. The number of viable RFP+GFP+ double-positive cells at day 10 was enumerated relative to fluorescent counting beads. RFP tracks integrated ACC1-specific shRNA hairpin; eGFP tracks mutant protein after dox induction. This experiment was performed 3 times with a representative graph shown. Bars represent standard deviation. ***, P F, Similar experiment using wild-type IDH cells. ACC1 was knocked down using shRNA#1 or shRNA#2 in THP-1 cells expressing IDH1 or IDH2 wild-type proteins under dox-induced promoter in lipid-depleted media. As in D, the number of viable RFP+GFP+ double-positive cells at day 10 was enumerated relative to fluorescent counting beads. RFP tracks integrated ACC1-specific shRNA hairpin; eGFP tracks wild-type protein after doxycycline induction. This experiment was performed 3 times with a representative shown. Bars represent standard deviation. NS, nonsignificant; NT, nontargeting shRNA.
Thus, we identified several differences in metabolism between mIDH1 and mIDH2 summarized in Fig. 3I. These include (i) defective reductive carboxylation supplying carbon by mutant IDH1 not rescued by ivosidenib; (ii) a greater NADPH deficit in mIDH1 versus mIDH2; (iii) increased acylcarnitine species (mIDH1 > mIDH2) compared with wild-type, indicating reliance on β-oxidation of fatty acids; and (iv) increased ACC1 dependence on β-oxidation for mIDH1 compared with mIDH2. In contrast, flux of glucose to produce glycerol-3-phosphate, the building block for glycerol and NADH cytoplasm to mitochondria shuttle, was not defective but rather upregulated in mIDH1. Together, our results support a model in which mIDH1 results in increased dependency to maintain both lipid production and lipid oxidation through ACC1, likely due to a longer-term NADPH deficit rather than a limited carbon supply. The NADPH deficit in primary cells and consequent derangements of lipid metabolism is of higher magnitude in mIDH1 compared with mIDH2. We propose that further impairment of de novo lipid synthesis through disruption of ACC1, first identified by MiSL, leads to impaired growth, thereby accounting for the synthetic lethal interaction. 041b061a72